Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …

Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has achieved tremendous
success treating B cell malignancies; however, some patients fail to respond due to poor …

A fundamental limitation of T cell therapies in solid tumors is loss of inflammatory effector
functions, such as cytokine production and proliferation. Here, we target a regulatory axis of …

Highlights•Gene editing using CRIPSR/Cas has the potential to increase anti-tumor efficacy
and persistence of adoptively transferred cells.•Allogeneic T cells can be made safer and …

Genome editing technologies have seen remarkable progress in recent years, enabling
precise regulation of exogenous and endogenous genes. These advances have been …

Loss of inflammatory effector function, such as cytokine production and proliferation, is a
fundamental driver of failure in T cell therapies against solid tumors. Here, we used …

Chimeric antigen receptor (CAR‐T) cell therapy is a newly developed immunotherapy
strategy and has achieved satisfactory outcomes in the treatment of hematological …

In a relatively short time, the pharmaceutical industry has witnessed a rapid integration of the
CRISPR technology in multiple areas of research, development, therapy, and diagnostics. A …

Chimeric antigen receptor T (CAR-T) cell therapy is the novel treatment strategy for
hematological malignancies such as acute lymphoblastic leukemia (ALL), lymphoma and …